Introduction
============

Bariatric surgery has been proved to be both effective and sustainable in the long-term weight-loss and remission of metabolic disorders ([@B1]; [@B68]). However, the underlying mechanisms are still far from fully elucidated. One interesting phenomenon observed after bariatric surgery is the increase of serum total bile acids. Actually, apart from the purely restrictive procedure, adjustable gastric banding (AGB) ([@B36]), it has been reported that all other types of bariatric surgery are associated with postsurgical increase of serum total bile acids ([@B73]; [@B3]; [@B19]; [@B27]). And this phenomenon has raised concern about the relationships between bile acids and bariatric surgery. Bile acids are known as the "intestinal soap," for their physiological effect on facilitating dietary fat and fat-soluble vitamin absorption. It is not until the late 1990s that bile acids had been found taking effect as signaling molecules ([@B46]). Most of the metabolic benefits of bile acids are mediated through nuclear or membrane receptors, or interaction with gut microbiota. In the present review, we focus on two major questions: (i) why serum bile acids are increased after bariatric surgery? (ii) how the altered bile acid metabolism contributes to the metabolic benefits of bariatric surgery?

Mechanisms of Serum Bile Acid Elevation After Bariatric Surgery
===============================================================

Bile acids are synthesized from cholesterols in the liver, stored in the gallbladder and expelled into the duodenum in response to enteral stimuli. Approximately, 95% of luminal bile acids are recycled into the portal vein in the terminal ileum and reutilized by the liver, forming the "enterohepatic circulation." Serum bile acids represent the excess bile acids that cannot be recycled by the liver during the enterohepatic circulation and thus present in the peripheral circulation. Increased serum bile acids may derive from increased synthesis in the liver, more reabsorption in the ileum and/or decreased excretion in the feces.

In Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD), shortened route of the enterohepatic circulation (the biliopancreatic limb and the common limb) expedites the contact of luminal bile acids with the ileum, a major area for bile acid reabsorption, leading to earlier and more active bile acid reabsorption ([@B19]). This explanation is also supported by an experimental procedure performed on rats termed ileal interposition (IT), in which the interposition of a segment of the ileum into the proximal jejunum shows greater bile acid reabsorption and increased serum bile acids ([@B11]). It has been speculated that the length ratio of the biliopancreatic limb and the common limb represent a major determinant of postoperative serum bile acid concentrations. Postoperative serum bile acid concentrations are likely to be greater with longer biliopancreatic limb and shorter common limb, as evidenced by both animal ([@B27]; [@B52]) and human studies ([@B51]). The precise mechanism has yet been elucidated. In BPD, the functional common limb left is less than one meter ([@B74]), and the increased luminal bile acid reabsorption cannot compensate for substantial fecal bile acid loss. Therefore, the increased hepatic bile acid synthesis also contributes to increased serum bile acids as a complementary mechanism ([@B69]; [@B19]). Compared to BPD, RYGB as well as duodenal-jejunal bypass (DJB, an experimental procedure designed to investigate the mechanism of diabetes remission with no effect on weight-loss), has enough intestinal bile acid reabsorption area, with either decreased ([@B13]) or unchanged fecal bile acid excretion ([@B42]; [@B5]), and the hepatic bile acid synthesis is decreased ([@B19]; [@B90]), probably due to a feedback regulation in response to the increased serum bile acids.

For vertical sleeve gastrectomy (VSG), only limited data are available regarding postsurgical serum bile acids. One human study showed immediate increase of serum bile acids after surgery ([@B34]), while two other human studies showed unchanged serum bile acids until 1 or 2 years after surgery, with only statistically non-significant increase ([@B57]; [@B26]). In contrast, animal studies showed consistently increased serum bile acids after VSG ([@B12]; [@B55],[@B56]). Due to the lack of direct anatomical manipulation of the gut, the increased serum bile acids after VSG are likely to be a secondary effect of altered gastrointestinal function ([@B72]) and progressively intestinal adaption. It has been reported that VSG accelerates gastric emptying and intestinal motility ([@B48]). And [@B56] has found decreased hepatic bile acid synthesis, increased intestinal villus length and enlarged bile acid reabsorption intestinal area, which might explain the increased serum bile acids after VSG.

Bile Acids, Fxr and Bariatric Surgery
=====================================

Role of FXR in Maintaining Bile Acid Homeostasis
------------------------------------------------

The farnesoid X receptor (FXR, NR1H4), an orphan member of the nuclear receptor family, was first identified as a natural receptor for bile acids in 1999 ([@B46]; [@B60]; [@B83]). Subsequently, bile acids were found transcriptionally regulating their own synthesis and enterohepatic transport by repressing CYP7A1 (a rate-limiting enzyme for bile acid synthesis in the liver) via hepatic FXR-SHP-CYP7A1 pathway ([@B24]; [@B43]). Later, fibroblast growth factor 19 (FGF19, in rodents ortholog FGF15), secreted mainly from the ileum in response to intestinal FXR activation, was found as an enterohepatic signal to regulate bile acid homeostasis as well ([@B28]). Circulating FGF15/19 within the portal venous system targets FGF receptor 4 (FGFR4) in the liver, and inhibits CYP7A1 expression and bile acid synthesis, thus working as components of a gut-liver signaling pathway that synergizes with hepatic FXR-SHP-CYP7A1 pathway to regulate bile acid homeostasis ([@B28]).

Role of FXR in Metabolism Regulation
------------------------------------

The metabolism-regulating effect of FXR is more complex compared to bile acid homeostasis maintenance. A variety of genetic and pharmacological animal models have been established to investigate the role of FXR signaling in body weight management and metabolism regulation. Whole body FXR knock-out mice (*FXR^-/-^*) displayed impaired glucose disposal and elevated blood glucose concentrations, as a result of blunted insulin pathway in the liver, peripheral adipose tissue and skeletal muscles, although FXR is not expressed in skeletal muscles ([@B9]; [@B44]). Meantime, plasma triglycerides, cholesterols and free fatty acids were elevated, with severe liver fat accumulation, however, surprisingly, this kind of mouse model was protected from diet- or genetically-induced obesity, probably because the adipocyte differentiation was impaired in the absence of FXR ([@B71]; [@B9]). In contrast, supplementation of whole-body FXR agonist (GW4064) in *ob/ob* mice has multiple beneficial effects, indicating that FXR could be a potential therapeutic target for metabolic disorders and bariatric surgery ([@B9]).

Since FXR is abundant in the liver and small intestine, some studies concentrate on its tissue-specific signaling. In the liver, FXR activation lowers plasma triglycerides via FXR-SHP-(SREBP-1c) pathway ([@B85]), and improves hyperglycemia by inhibiting gluconeogenesis and improving insulin sensitivity ([@B92]). In contrast, liver-specific *FXR^-/-^* mice showed increased plasma triglycerides, and unlike whole-body FXR knock-out, were not protected from diet-induced obesity and insulin resistance ([@B85]). In the small intestine, the physiological role of FXR is primarily mediated by FGF15/19 whose metabolism-beneficial functions resemble those of insulin in stimulating protein and glycogen synthesis and inhibiting gluconeogenesis, but does not lead to body weight gain or hepatic fat accumulation ([@B35]).

Bile Acid-FXR Pathway in Bariatric Surgery
------------------------------------------

Since bile acids are natural ligands for FXR, it has been believed that bile acid-FXR pathway contribute to the beneficial effects of bariatric surgery. However, no consensus has been reached so far. The essential role of FXR in bariatric surgery was first demonstrated by a milestone research published in 2014. The ability of VSG to reduce body weight and improve glucose tolerance was substantially reduced in the state of genetic disruption of FXR ([@B66]). Nevertheless, the results were later questioned by the authors themselves, as the whole body FXR knock-out mice *per se* were protected from diet-induced obesity as well as glucose intolerance, and the observational window might not be long enough ([@B7]). Bariatric surgery alters bile acid drainage, either anatomically or functionally, and changes luminal bile acid concentrations and composition. Activation of intestinal FXR by bile acids increases FGF19 following bariatric surgery in humans and represents one mechanism accounting for postsurgical metabolic improvement ([@B31]; [@B61]; [@B22]; [@B26]; [@B33]; [@B67]). One human study did not support the contribution of FGF19 to the benefit of RYGB, as the increase of FGF19 did not parallel the improvement of glucose tolerance ([@B33]). And animal studies have shown that both intestine-specific FXR agonist (Fexaramine) ([@B17]) and antagonist (Glycine-muricholic acid) ([@B32]) have the capacity of reducing body weight and improving metabolism. Interestingly, alteration of luminal bile acids after bariatric surgery did not guarantee activation of intestinal FXR. On the contrary, intestinal FXR was intact or even repressed ([@B37]; [@B23]). These unexpected phenomena have been thought closely related to the intestinal bile acid milieu, as the physiological effect of each individual bile acid differs in interacting with FXR, with chenodeoxycholic acid (CDCA) being a potent agonist, deoxycholic acid (DCA) being a moderate agonist ([@B60]), yet ursodeoxycholic acid (UDCA) ([@B53]), and muricholic acid (MCA, only in rodents) being antagonists ([@B32]). Surprisingly, intestinal FXR repression also leads to metabolic benefits. One study reported that FXR repression within intestinal L cells led to glucagon-like peptide 1 (GLP-1) secretion hence improving glucose metabolism ([@B77]). This finding may also partly explain the paradox between intestinal bile supplementation and bile deprivation (e.g., bile sequestrant), both of which have been confirmed effective in enhancing GLP-1 secretion ([@B77]; [@B90]).

It should be noted that most of the studies identifying intestinal FXR repression as a positive metabolic regulator are from animal models, suggesting that the gut may respond differently to FXR-specific targeting between animals and humans.

Bile Acids, Tgr5, and Bariatric Surgery
=======================================

G protein coupled receptor 1, also known as TGR5 (GPR131), was discovered as a membrane-type receptor for bile acids in 2002 ([@B49]) and has been confirmed as another essential receptor in maintaining glucose homeostasis after sleeve gastrectomy ([@B50]). However, one latest report revealed that the metabolic benefits were still maintained in *Tgr5^-/-^*, but not *Fxr*^![](fphys-10-00374-i001.jpg)/*E*^ mice after a bariatric procedure, suggesting a less important role for TGR5 as opposed to intestinal FXR ([@B2]). Unlike FXR, each individual bile acid is capable of activating TGR5, only with different potency (conjugated form \> unconjugated form, LCA \> DCA \> CDCA \> CA) ([@B49]). Therefore, after bariatric surgery, the increased luminal or serum bile acids are able to elicit TGR5-mediated metabolic benefits, and appear to make a complementary contribution to the metabolic benefits of bariatric surgery.

Luminal Bile Acids, TGR5, and Incretins
---------------------------------------

In the distal small intestine, TGR5 activation within enteroendocrine L cells in response to luminal bile acids have been confirmed as a critical signaling pathway in promoting GLP-1 secretion in both animal models ([@B75]) and humans ([@B86]). Following bariatric surgery, as a result of gut manipulation and increased luminal bile acids, serum GLP-1 has been found ubiquitously elevated, either acutely ([@B40]) or gradually ([@B6]), and is now referred to as an important, albeit not exclusive, mechanism of bariatric surgery in improving glucose tolerance ([@B45]). GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are known as "incretin hormones" as they mediate the incretin effect, defined as the increased stimulation of insulin secretion elicited by oral compared with intravenous administration of glucose under similar plasma glucose levels ([@B88]). In health, the incretin effect accounts for 70% of postprandial insulin secretion after oral ingestion of glucose in a glucose-dependent fashion ([@B58]). In T2DM, the incretin effect is markedly impaired as a result of the loss of insulinotropic effect of GIP, while GLP-1 still maintains its pleiotropic physiological functions including stimulating insulin secretion, improving hepatic insulin sensitivity and suppressing appetite ([@B87], [@B88]), which might account for the partially restored incretin effect after bariatric surgery ([@B38]). A latest "proof of concept" study has proved that the distal, as opposed to proximal, small intestine is superior in modulating postprandial glucose metabolism in both health and T2DM, of which GLP-1 plays a major role ([@B91]). Currently, GLP-1 analogs as well as dipeptidyl peptidase-4 (DDP4, an enzyme for degradation of incretins) inhibitors have been commercialized for the management of T2DM.

Serum Bile Acids, TGR5, and Energy Expenditure
----------------------------------------------

In the skeletal muscle and brown adipose, increased serum bile acids have the capacity of converting tetraiodothyronine (T4) to triiodothyronine (T3) through TGR5, leading to more energy expenditure, which might facilitate weight loss ([@B36]; [@B8]; [@B84]). However, the relevance between TGR5-mediated energy expenditure and bariatric surgery has not been clarified. In a human study, increased skeletal gene expressions of TGR5 downstream targets (mitochondrial COX IV and Kir6.2) were detected after RYGB, but no correlation with resting energy expenditure was found ([@B36]). In addition, the majority of studies suggest decreased energy expenditure after bariatric surgery, which might be a secondary effect of weight loss ([@B4]; [@B10]). In contrast, increased weight-adjusted energy expenditure was also present in some studies ([@B18]; [@B64]). As energy metabolism is related to many factors, such as body composition, exercise or hormones, whether TGR5-mediated energy regulation plays a role in weight-loss after bariatric surgery still warrants further research.

Microbiota and Bile Acids
=========================

Role of Gut Microbiota in Metabolic Disorders
---------------------------------------------

Gut microbiota, also named as "The Second Genome," consists of more than 10^14^ microorganisms, most of which have not been fully investigated ([@B80]). Five phyla dominate human gut community, including Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia, of which Bacteroidetes and Firmicutes account for over 90% of the whole gut microbiota ([@B76]). Along the whole gut, microbiota is not uniformly distributed. Both the abundance and diversity are increased from the proximal to distal gut ([@B62]). In the stomach, only bacteria resistant to acidic environment survive (e.g., *Lactobacillus* or *Streptococcus* or *Veillonella*) ([@B15]), while in the large intestine, where the intrinsic environment is suitable for bacterial growth, lives most of the gut bacteria ([@B62]). Gut microbiota begins to colonize since newborns, and is related to certain pathological states in adulthood. An identical twin study showed that different physiologic states (obese versus lean) are associated with distinct gut microbiota, despite the same genetic background ([@B79]). In obesity, the majority of animal and human studies have demonstrated that the diversity of gut microbiota is decreased, and Phylum Firmicutes is increased at the expense of Phylum Bacteroidetes, independent of food consumption ([@B41]; [@B81], [@B79]). In T2DM, inconsistent results have been reported. Larsen et al. found that the proportions of Phylum Firmicutes and Class Clostridia were significantly reduced in T2DM, and Bacteroidetes/Firmicutes ratio was correlated positively and significantly with plasma glucose concentrations ([@B39]). Qin et al. used a deep shotgun sequencing method analyzing gut microbial DNA from 345 Chinese individuals, and found that type 2 patients had a moderate degree of gut bacterial dysbiosis, a decline in butyrate-producing bacteria and an increase in diverse opportunistic pathological bacteria ([@B63]). They also pointed out that compared to inflammatory bowel disease (IBD), the degree of gut microbiota changes in T2DM was not that substantial. Since gut microbiota is influenced by various factors such as life style, dietary, disease, medication, and surgery, the currently available results should be interpreted with caution, and may not be used as a marker for T2DM monitoring at the moment.

Changes of Gut Microbiota After Bariatric Surgery
-------------------------------------------------

Bile acids and gut microbiota are reciprocally affected and are both altered by bariatric surgery. Within the enterohepatic circulation, bile acids in the distal ileum and colon undergo hydrolysis (deconjugation) and subsequent transformation into secondary bile acids. These processes require the catalysis of bile salt hydrolases (BSHs, produced by certain gut bacteria) and the bacterial activity of 7α-dehydroxylation ([@B65]). Meantime, both gut bile acid concentrations and compositions have direct influence on gut microbiota. Increased luminal bile acid concentrations have anti-bacterial effects, killing certain strains of bacterium and make some other bacteria (e.g., *Bilophila wadsworthia*) thrive ([@B59]; [@B14]). Furthermore, some individual bile acids are capable of activating enteral FXR, thus leading to enteroprotection by promoting related gene expressions and inhibits bacterial overgrowth and mucosal injury in the ileum. All these effects indicate the existence of indirect influence on gut microbiota by gut bile acids ([@B29]). Following bariatric surgery, gut microbiota is changed. In RYGB, at the phylum level, Proteobacteria has been reported to be increased at the expense of Firmicutes ([@B89]; [@B78]), while Bacteroidetes has been found inconsistently changed, either increased ([@B21]) or decreased ([@B42]; [@B25]). In VSG, both animal and human studies showed increased Bacteroidetes and decreased Firmicutes, and rebuilt of the gut microbiota diversity ([@B30]; [@B54]; [@B70]). At the species level, the outcomes have been inconsistently reported across different studies, further increasing the difficulty of gut microbiota research. As to the interaction of bile acids and gut microbiota after bariatric surgery, it's similar to an old question: "which came first, the chicken or the egg?" We do not have direct and strong evidence at the moment, but assume that the instantly altered luminal bile acids following bariatric surgery might be the driving force, and the final phenotype of luminal bile acids and gut microbiota is a result of gradual interaction and adaption of each other.

Gut Microbiota After Bariatric Surgery: A Signal Carrier?
---------------------------------------------------------

Another question to be answered is how gut microbiota affects the host after bariatric surgery. In fact, the contribution of gut microbiota to the metabolic benefits after bariatric surgery has not been clarified. Based on currently available reports, gut microbiota is likely to be a signal carrier and transmits signals that are able to play a role even in a different host. Direct evidence comes from fecal microbiota transplantation (FMT). Patients with metabolic syndrome experienced significantly increased insulin sensitivity after receiving gut microbiota from lean donors ([@B82]). However, the improvement of insulin sensitivity disappeared at 12 weeks after FMT, suggesting that the beneficial effect of FMT might not last in absence of sustainable exogenous stimulations. Metabolic benefits were also observed in FMT from bariatric surgery recipient donors to mice ([@B78]), but we do not know whether the effect of bariatric surgery could be recapitulated by FMT in human recipient as well.

Due to technical reasons, it's difficult to observe the dynamic change of luminal bile acids and gut microbiota frequently after bariatric surgery. And a Dutch population-based cohort showed that the influence of currently realized exogenous and intrinsic host factors could only explain 18.7% of the inter-individual variation of microbial composition ([@B93]). Therefore, the knowledge of gut microbiota is far from enough and warrants future research.

Bile Diversion Procedures
=========================

In order to isolate the contribution of bile acids to the metabolic benefits of bariatric surgery, some studies have tried to manipulate bile flow directly without altering the gastrointestinal tract ([Table 1](#T1){ref-type="table"}). Bile diversion (BD) procedure in rats was performed as early as the 1980s, even before the discovery of GLP-1, to investigate the influence of re-routing of bile flow on glucose homeostasis. This early study showed 10% less weight of rats undergoing BD than control, decreased fasting blood glucose and improved glucose tolerance, with no effect on insulin secretion ([@B47]). Another study in 1991 using streptozocin (STZ) -induced diabetic rats showed similar results, except an immediate return of insulin to normal level after surgery ([@B16]). It is not until 2013 that the BD procedure had regained attention. Subsequent studies have demonstrated comparable effects of BD with gastric bypass procedure in glucose control in normal rats ([@B23]), diet-induced obese rats ([@B37]), and mice ([@B20]). However, under diabetic state, the effects of BD were attenuated compared to DJB, with limited glucose-lowering effect observed. Therefore, to our knowledge, bile acid manipulation appears to be capable of recapitulating the effects of bariatric surgery only in non-diabetic state.

###### 

Bile diversion procedures.

  Year   Author         Journal             Model                       Diversion site                        Weight          Fasting glucose   Glucose tolerance   Insulin         GLP-1
  ------ -------------- ------------------- --------------------------- ------------------------------------- --------------- ----------------- ------------------- --------------- -----------
  1985   Manfredini G   Am J Physiol        Wistar rats                 Second jejunal loop                   ↓ (week 1)      ↓ (week 1)        ↓ (week 1)          ---             N/A
  1991   Ermini M       Acta Diabetol Lat   STZ-induced diabetic rats   Second jejunal loop                   ↓ (instantly)   ↓ (instantly)     N/A                 ↓ (instantly)   N/A
  2013   Kohli R        Endocrinology       Long-Evans obese rats       15, 30 cm distal to Treitz ligament   --- (week 5)    ↓ (week 5)        ↓ (week 5)          ↓ (week 4)      ↑ (week4)
  2015   Flynn CR       Nat Commun          Diet-induced obese mice     Ileum                                 ↓ (week 8)      ↓ (week 4)        ↓ (week 2)          ↓ (week 8)      N/A
  2015   Goncalves D    Ann Surg            Sprague-Dawley rats         Mid-jejunum and mid-ileum             --- (day 9)     --- (day 10)      ↓ (day 10)          ↑ (day 10)      N/A
  2015   Zhang X        Obes Surg           STZ-induced diabetic rats   25 cm distal to Treitz ligament       ↓ (week 8)      ↓ (week 2)        ↓ (week 8)          ---             ↑ (week8)
                                                                                                                                                                                    

Conclusion
==========

Bile acids play a role in metabolic regulation through various pathways. Alteration of bile acid metabolism is an important component of bariatric surgery, and represents a promising target for the management of metabolic disorders.
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